Futura Medical Share Discussion Threads

[dontshoutatonce] 23/4/2023 15:19

Wrong. 10 seconds ago.

[broomrigg] 23/4/2023 12:44

Last sale of Eroxon via boots.com......29 seconds ago.Nice ;-)

[lbo] 23/4/2023 10:48

Didn't the brokers say something similarly vague before the last convertible loan transaction happened!? LOL

[petroc] 23/4/2023 10:46

I'm surprised you've got the time to post on here, with all the 1 star reviews you keep dumping on Boots and Farmaline! You're never going to keep up with all the genuine 5 stars though!

[lbo] 23/4/2023 10:45

Why didn't the multi-ID ramper state all the Liberum disclaimers, disclosures and the assumptions that the research and price target is based upon! Like being based on the long term 'expected' sales estimates that Futura 'believe' they could achieve and give them LOLhttps://liberum.com/research-disclaimer/https://liberum.com/research-disclosures/Like the brokers admitting in their previous research they are assuming the original Med2002/2005 patents which expire in 2025 in EU and USA in 2028 will provide some protection to Med3000 until then. Thats a big assumption as the original patent was an umbrella patent covering Dermasys with GTN. Med3000 is just Dermasys on its own which dates back to 2002 and is now just a medical device delivering only a cooling sensation via ˜evaporative cooling’Also just like it was also believed by brokers at one time that PET500 and CSD500 would generate millions of pounds of revenues for shareholders. Yet they didn’t and both failed to meet previously believed expectations! ROFLMAOhttps://www.yumpu.com/en/document/read/35483851/fum-initiation-note-sept-2014-final'These forward-looking statements may use words such as "aim", "anticipate", "believe", "could", "may", "intend", "estimate", "expect" and words of similar meaning. By their nature, all forward-looking statements involve risk and uncertainty because they relate to future events and circumstances which are beyond the control of the Company'https://www.investorschronicle.co.uk/2011/12/06/tips-and-ideas/share-tips/tips-of-the-week/futura-medical-fum-gzYWSNgGma4WXndOKPDM9O/article.htmlIt was estimated that CSD500 could capture about 6 per cent of the condom branded market, which would mean roughly £35m a year in sales for SSL. Assuming a percentage royalty take for Futura in the late teens, CSD500 could be generating over £6m a year in sales for the groupAnd ‘Futura estimated it would receive royalties of £1.7-2.5m per annum per 1% of global market sharehttps://www.edisoninvestmentresearch.com/?ACT=18&ID=2666

[lbo] 23/4/2023 10:38

‘without needing to turn to equity markets’

So its a convertible loan then! LOL

From Trinity:

‘visibility is currently limited on the magnitude of potential revenues’

Will it even be enough to cover the annual salaries and bonuses!?

Liberum:

‘Given the lack of visibility with regards to either timing or quantum of these revenues’

‘We leave our forecasts largely unchanged’

So more losses for 2023!



a agreed percentage of the net sales value (after transport costs, sales tax, credit notes for returns and defective products and any settlement, retrospective, volume and promotional discounts) charged by LRC or any sub-licensee in relation to the Product.

The royalty and the royalty advance may be reduced by such amount (if any) as is agreed or determined by an expert to be fair and reasonable if: (i) any patent application does not proceed to grant or any patent rights are determined to be unenforceable or are revoked or lapse; or (ii) an event occurs which in LRC reasonable opinion adversely affects the commercial viability of the licence agreement or the margins on sales of the Product; or (iii) a competing product is offered

[petroc] 23/4/2023 10:36

'Liberum repeated its buy recommendation and 121p a share price target for the stock in early April 23.
They also state:
Encouragingly, as the launch of Eroxon builds in Europe, Futura expects to generate maiden commercial revenues this year.
Given the lack of visibility with regards to either timing or quantum of these revenues, we haven't yet factored them into our forecasts, but these, together with other potential sources of income mean that we are very comfortable that Futura is well funded to deliver without needing to turn to equity markets, said Liberum in a note to clients.

I repeat, 'WITHOUT NEEDING TO TURN TO EQUITY MARKETS'

So it looks like LiarBO has got it spectacularly wrong yet again.

[lbo] 23/4/2023 10:35

Very high chance now of another ˜innovative deal’ for funding via a convertible loan which converts at a hefty discount is on the way for the USA like was done with China. And why wouldn’t they hedge their their bets in terms of being able to continue paying all the salaries, bonuses and options even if a possible issue/delay with the De Novo medical device registration arises and the current cash runway runs out!

Market Cap is now near £160m for a company with Zero revenues and at best will have a few million pa revenues from Eroxon yet it has no real enforceable patent and the cooper deal only has few years left. All on a placebo gel that is just made of alcohol, water, glycol and Carbopol!






Death-Spiral Convertible Financier Has a Lot of Fun

[lbo] 23/4/2023 10:28

Liberum says ‘other potential sources of income’

Like a convertible loan! Like Flexiseq did!LOL




The secured loan of US$15 million, which matures on June 25, 2018, will bear interest at 12% per annum plus other additional consideration. The interest rate will decrease to 10% if Pro Bono Bio meets certain equity-fundraising targets. The loan is secured by a charge over the assets of Pro Bono Bio and its affiliates which includes but is not limited to Flexiseqâ„¢, an innovative topical pain product that has sales of more than 3 million units since its U.K. launch last year.



In 2017, PBB was on the verge of bankruptcy, because it could not pay interest on the loan of 15 million pounds, taken in 2015 by the Canadian Knight Therapeutics.



Futura medical brokers still forecasting more losses for 2023 so yes a fundraising or another Co-High type financial transaction is on the way!



‘Therefore, from June 2022 it had roughly 13 months of cash runway’

‘it's fair to say the end of the cash runway is in sight’

[lbo] 23/4/2023 10:27

Come on pumpty dumpties! Sell the fundraising or convertible loan! LOLhttps://www.proactiveinvestors.co.uk/companies/news/306698/futura-chief-hails-very-exciting-times-after-saudi-launch-of-erectogenic-condom-6698.html

[lbo] 23/4/2023 10:25

LOL'Exciting times' ahead indeed!!! loobrush - 11 May 2015 - 08:32:49 - 69 of 1826811 MayRNS this morning-retail roll out to 600 stores-excellent news on the CSD front-the online and now retail roll out is setting up the template for roll out across Europe and then worldwide.This will sort out any bugs in the methods being used and provide a template for other launches so that faster adoption can be achieved worldwide.Lots of news yet to come over the next couple of months on shelf life and pain portfolio trials, also I would expect more launches to be announced. From now on could get quite exciting. After a small pullback should start to get price moving up again.

[petroc] 23/4/2023 10:23

Phew! That must have hurt, pasting that story, LiarBO. It must have set off memories of when you used to have money, before throwing it all away on CSD500 with your pathetic investment methods. Hahahaha! You've been bitter ever since, six years of stock bashing! What a massive loser!

[broomrigg] 23/4/2023 09:08

First sales check today on the boots.com website at 0905 hrs ......Last Eroxon sale 10 seconds ago.Love it :-)